Molecular mechanism of tumor associated hypercoagulability

doi:10.3760/cma.j.issn.1673-422X.2016.05.009

Abstract

Abstract: The process of tumorigenesis, local invasion and distant metastasis will produce a series of molecular changes, these genetic mutation or abnormal expression of molecules play a promoting role in hypercoagulation. At the same time, hypercoagulation also increases the risk of tumor progression. It is important to understand their specific processes and the molecular role, and it can provide theoretical basis for better management of patients, and has significance for developing more effective and security new anticlotting drugs.

Key words: Neoplasms, Blood coagulation, Molecular mechanism

Zhang Xue, Jiang Da, Li Ying. Molecular mechanism of tumor associated hypercoagulability[J]. Journal of International Oncology, 2016, 43(5): 356-359.

References

［1］赵晶, 姜达. 恶性肿瘤高凝状态及其干预［J］. 癌症进展, 2013, 11(1): 48-52. ［2］陈国荣. 恶性肿瘤患者血栓的形成机制与诊断进展［J］. 新乡医学院学报, 2015, 32(9): 891-893. ［3］ Anand M, Brat DJ. Oncogenic regulation of tissue factor and thrombosis in cancer［J］. Thromb Res, 2012, 129 Suppl 1: S46-S49. DOI: 10.1016/S00493848(12)700154. ［4］付晓飞, 杨之斌, 殷正丰. 血小板与循环肿瘤细胞［J］. 肿瘤, 2014, 34(3): 286-290. ［5］ Grane CA, Han SJ, Barry JJ, et al. TGFbeta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients［J］. Neuro Oncol, 2010, 12(1): 7-13. DOI: 10.1093/neuonc/nop009. ［6］ Gigante M, Gesualdo L, Ranieri E.TGFbeta: a master switch in tumor immunity［J］. Curr Pharm Des, 2012, 18(27): 4126-4134. ［7］ Van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside［J］. Blood, 2012, 119(4): 924-932. DOI: 10.1182/blood201106317685. ［8］ Godby RC, van den Berg YW, Srinvasan RS, et al. Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrinmediated signaling in murine models［J］. Mol Med, 2012, 18(1): 771-779. DOI: 10.2119/molmed.2011.00416. ［9］ Srinivasan R, Ozhegov E, van den Berg YW, et al. Splice variants of tissue factor promote monocyteendothelial interactions by triggering the expression of cell adhesion molecules via integrinmediated signaling［J］. Thromb Haemost, 2011, 9(10): 2087-2096. DOI: 10.1111/j.15387836.2011.04454. ［10］ Ettelaie C, Collier ME, Mei MP, et al. Enhanced binding of tissue factor microparticles to collagenⅣ and fibronectin leads to increased tissue factor activity in vitro［J］. Thromb Haemost, 2013, 109(1): 61-71. DOI: 10.1160/TH12050279. ［11］ Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations［J］. Proc Natl Acad Sci USA, 2014, 111(9): 3544-3549. ［12］ Breij EC, de Goeij BE, Verploegen S, et al. An antibodydrug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors［J］. Caner Res, 2014, 74(4): 1214-1226. DOI: 10.1158/00085472.CAN132440. ［13］ Garnier D, Magnus N, Lee TH, et al. Cancer cells induced to express mesenchymal phenotype release exosomelike extracellular vesicles carrying tissue factor［J］. J Biol Chem， 2012, 287(52): 43565-43572. DOI: 10.1074/jbc.M112. 401760. ［14］ Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissuefactorbearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation［J］. Blood, 2005, 106(5): 1604-1611. ［15］ Hathcock J, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Ⅹa［J］. Blood, 2004, 104(1):123-127. ［16］ Zwicker JI, Liebman H, Neuberg D, et al. Tumorderived tissue factorbearing microparticles are associated with venous thromboembolic events in malignancy［J］. Clin Cancer Res, 2009, 15(22): 6830-6840. DOI: 10.1158/10780432. CCR090371. ［17］ Nadir Y, Brenner B. Heparanase multiple effects in cancer［J］. Thromb Res, 2014, 133Suppl 2: S90-S94. DOI: 10.1016/S00493848(14)500151. ［18］ Menschikowski M, Hagelgans A, Tiebel O, et al. Regulation of thrombomodulin expression in prostate cancer cells［J］. Cancer Lett, 2012, 322(2): 177-184. DOI: 10.1016/j.canlet.2012.03.001. ［19］ Chen LM, Wang W, Lee JC, et al. Thrombomodulin mediates the progression of epithelial ovarian cancer cells［J］. Tumour Biol, 2013, 34(6): 3743-3751. DOI: 10.1007/s132770130958x. ［20］ Demers M, Wagner DD. Neutrophil extracellular traps: A new link to cancerassociated thrombosis and potential implications for tumor progression［J］. Oncol Immunol, 2013, 2(2): e22946. ［21］ Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancerassociated thrombosis［J］. Proc Natl Acad Sci USA, 2012, 109(32): 13076-13081. DOI: 10.1073/pnas.1200419109. ［22］ Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases［J］. Nat Med， 2010, 16(8): 887-896. DOI: 10.1038/nm.2184. ［23］ Buck K, Hug S, Seibold P, et al. CD24 polymorphisms in breast cancer: impact on prognosis and risk［J］. Breast Cancer Res Treat, 2013, 137(3): 927-937. DOI: 10.1007/s1054901223259. ［24］ Bretz NP, Salnikov AV, Perne C, et al. CD24 controls Src/STAT3 activity in human tumors［J］. Cell Mol Life Sci, 2012, 69(22): 3863-3879. DOI: 10.1007/s0001801210559. ［25］ Kang KS, Choi YP, Gao MQ, et al. CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype［J］. Biochem Biophys Res Commun, 2013, 432(2): 333-338. DOI: 10.1016/j.bbrc.2013.01.102. ［26］ Rao B, Gao Y, Huang J, et al. Mutations of p53 and Kras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis［J］. Int J Colorectal Dis, 2011, 26(5): 593-601. DOI: 10.1007/s00384 01111641. ［27］ Yu JL, Xing R, Milsom C, et al. Modulation of the oncogenedependent tissue factor expression by kinase suppressor of ras1［J］. Thromb Res, 2010, 126(1): e6-e10. DOI: 10.1016/j.thromres.2010.04.014.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.